Pacira | PCRX - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
Astellas Pharma JPY 215.07B 19.63B 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Cara Therapeutics USD 2.09M 96K 2026-03
Coherus Biosciences USD 15M 6.26M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
J&J USD 6.25B 168M 2026-09
Ligand Pharmaceuticals USD 29.12M 8.29M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Novo Nordisk DKK 16.31B 3.09B 2026-06
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 91.81M 7.93M 2026-06
Perrigo USD 3.28B 3.02B 2026-06
Pfizer USD 3.41B 496M 2026-06
Supernus Pharmaceuticals USD 133.64M 15.41M 2026-06
Teva Pharmaceutical Industries USD 1.03B 34M 2026-06
Xeris Pharmaceuticals USD 53.14M 10.51M 2026-03
Zoetis USD 592M 4M 2026-06